TESTOPEL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Testopel, and when can generic versions of Testopel launch?
Testopel is a drug marketed by Endo Operations and is included in one NDA.
The generic ingredient in TESTOPEL is testosterone. There are sixty-nine drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the testosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Testopel
A generic version of TESTOPEL was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TESTOPEL?
- What are the global sales for TESTOPEL?
- What is Average Wholesale Price for TESTOPEL?
Summary for TESTOPEL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 2 |
Drug Prices: | Drug price information for TESTOPEL |
DailyMed Link: | TESTOPEL at DailyMed |
![TESTOPEL drug patent expirations Drug patent expirations by year for TESTOPEL](/p/graph/s/t/TESTOPEL-patent-expirations.png)
![Drug Prices for TESTOPEL](/p/graph/drug-price/TESTOPEL.png)
Recent Clinical Trials for TESTOPEL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Empower Pharmacy | Phase 3 |
University of Miami | Phase 3 |
Men's Health Boston | Phase 1 |
Pharmacology for TESTOPEL
Drug Class | Androgen |
Mechanism of Action | Androgen Receptor Agonists |
US Patents and Regulatory Information for TESTOPEL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Operations | TESTOPEL | testosterone | PELLET;IMPLANTATION | 080911-001 | Approved Prior to Jan 1, 1982 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for TESTOPEL
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Warner Chilcott UK Ltd. | Intrinsa | testosterone | EMEA/H/C/000634 Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
Warner ChilcottĀ Deutschland GmbH | Livensa | testosterone | EMEA/H/C/000630 Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |